Advertisement

WDR34 Activates Wnt/Beta-Catenin Signaling in Hepatocellular Carcinoma

  • Xiaoling Luo
  • Yuting Liu
  • Shijie Ma
  • Lei Liu
  • Rui Xie
  • Shaochuang WangEmail author
Original Article
  • 20 Downloads

Abstract

Background

Wnt ligand binding initiates the interaction between Frizzled and Dvl proteins. However, the regulation of Frizzled–Dvl proteins interaction remains largely unknown.

Aims

The present study aims to elucidate the regulation of Frizzled–Dvl interaction by WDR34.

Methods

The protein levels of WDR34 in hepatocellular carcinoma (HCC) tissues were examined by western blot and immunohistochemistry. The effects of WDR34 on the growth and migration of HCC cells were examined using MTT assay and Boyden chamber assay. The interaction between Frizzled and Dvl was evaluated by immunoprecipitation and GST pull-down assay.

Results

In this study, we have shown that WDR34, the binding protein of Frizzled (Fz) activated beta-catenin/TCF signaling by enhancing the interaction between Fz and Dvl2. WDR34 was found to up-regulate in HCC tissues, and its expression was negatively correlated with the survival of HCC patients. WDR34 promoted the growth, colony formation and migration of HCC cells. However, knocking down the expression of WDR34 inhibited the growth, colony formation and migration of HCC cells.

Conclusion

Taken together, this study demonstrated the oncogenic roles of WDR34 in the progression of HCC and suggested that WDR34 might be a therapeutic target for HCC.

Keywords

Hepatocellular carcinoma Beta-catenin/TCF signaling WDR34 Cell growth and migration 

Notes

Author’s contribution

Shaochuang Wang designed this project. Xiaoling Luo, Yuting Liu, Shijie Ma, Lei Liu and Rui Xie performed the experiments.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights

All applicable international, national and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

References

  1. 1.
    Ren YJ, Huang T, Yu HL, et al. Expression of beta-catenin protein in hepatocellular carcinoma and its relationship with alpha-fetoprotein. J Huazhong Univ Sci Technol Med Sci. 2016;36:846–851.  https://doi.org/10.1007/s11596-016-1673-9.CrossRefGoogle Scholar
  2. 2.
    Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/beta-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol. 2016;22:823–832.  https://doi.org/10.3748/wjg.v22.i2.823.CrossRefGoogle Scholar
  3. 3.
    Waisberg J, Saba GT. Wnt/beta-catenin pathway signaling in human hepatocellular carcinoma. World J Hepatol. 2015;7:2631–2635.  https://doi.org/10.4254/wjh.v7.i26.2631.CrossRefGoogle Scholar
  4. 4.
    Kypta RM, Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9:418–428.  https://doi.org/10.1038/nrurol.2012.116.CrossRefGoogle Scholar
  5. 5.
    Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5:691–701.  https://doi.org/10.1038/nrg1427.CrossRefGoogle Scholar
  6. 6.
    Allison SJ. Development: beta-catenin network controls nephron patterning. Nat Rev Nephrol. 2015;11:195.  https://doi.org/10.1038/nrneph.2015.22.CrossRefGoogle Scholar
  7. 7.
    McCrea PD, Gottardi CJ. Beyond beta-catenin: prospects for a larger catenin network in the nucleus. Nat Rev Mol Cell Biol. 2016;17:55–64.  https://doi.org/10.1038/nrm.2015.3.CrossRefGoogle Scholar
  8. 8.
    Chen J, Rajasekaran M, Hui KM. Atypical regulators of Wnt/beta-catenin signaling as potential therapeutic targets in hepatocellular carcinoma. Exp Biol Med (Maywood). 2017;242:1142–1149.  https://doi.org/10.1177/1535370217705865.CrossRefGoogle Scholar
  9. 9.
    Fan X, Ma X, Cui L, et al. CARF activates beta-catenin/TCF signaling in the hepatocellular carcinoma. Oncotarget. 2016;7:80404–80414.  https://doi.org/10.18632/oncotarget.13138.Google Scholar
  10. 10.
    Wang LY, Li B, Jiang HH, Zhuang LW, Liu Y. Inhibition effect of miR-577 on hepatocellular carcinoma cell growth via targeting beta-catenin. Asian Pac J Trop Med. 2015;8:923–929.  https://doi.org/10.1016/j.apjtm.2015.10.001.CrossRefGoogle Scholar
  11. 11.
    Kitao A, Matsui O, Yoneda N, et al. Hepatocellular carcinoma with beta-catenin mutation: imaging and pathologic characteristics. Radiology. 2015;275:708–717.  https://doi.org/10.1148/radiol.14141315.CrossRefGoogle Scholar
  12. 12.
    Jiao Y, Ban KC, Cao J, Yue HY, Luo Y, Su JJ. Expression and exon 3 mutation of beta-catenin in human hepatocellular carcinoma. Ai Zheng. 2007;26:1085–1089.Google Scholar
  13. 13.
    Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene. 2006;25:3778–3786.  https://doi.org/10.1038/sj.onc.1209547.CrossRefGoogle Scholar
  14. 14.
    Park JY, Park WS, Nam SW, et al. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int. 2005;25:70–76.  https://doi.org/10.1111/j.1478-3231.2004.0995.x.CrossRefGoogle Scholar
  15. 15.
    Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002;21:4863–4871.  https://doi.org/10.1038/sj.onc.1205591.CrossRefGoogle Scholar
  16. 16.
    Gao D, Wang R, Li B, Yang Y, Zhai Z, Chen DY. WDR34 is a novel TAK1-associated suppressor of the IL-1R/TLR3/TLR4-induced NF-kappaB activation pathway. Cell Mol Life Sci. 2009;66:2573–2584.  https://doi.org/10.1007/s00018-009-0059-6.CrossRefGoogle Scholar
  17. 17.
    Kessler K, Wunderlich I, Uebe S, et al. DYNC2LI1 mutations broaden the clinical spectrum of dynein-2 defects. Sci Rep. 2015;5:11649.  https://doi.org/10.1038/srep11649.CrossRefGoogle Scholar
  18. 18.
    Gholkar AA, Senese S, Lo YC, et al. Tctex1d2 associates with short-rib polydactyly syndrome proteins and is required for ciliogenesis. Cell Cycle. 2015;14:1116–1125.  https://doi.org/10.4161/15384101.2014.985066.CrossRefGoogle Scholar
  19. 19.
    McInerney-Leo AM, Harris JE, Leo PJ, et al. Whole exome sequencing is an efficient, sensitive and specific method for determining the genetic cause of short-rib thoracic dystrophies. Clin Genet. 2015;88:550–557.  https://doi.org/10.1111/cge.12550.CrossRefGoogle Scholar
  20. 20.
    Schmidts M, Vodopiutz J, Christou-Savina S, et al. Mutations in the gene encoding IFT dynein complex component WDR34 cause Jeune asphyxiating thoracic dystrophy. Am J Hum Genet. 2013;93:932–944.  https://doi.org/10.1016/j.ajhg.2013.10.003.CrossRefGoogle Scholar
  21. 21.
    Mares J, Szakacsova M, Soukup V, Duskova J, Horinek A, Babjuk M. Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results. Neoplasma. 2013;60:295–301.CrossRefGoogle Scholar
  22. 22.
    Dijksterhuis JP, Baljinnyam B, Stanger K, et al. Systematic mapping of WNT-FZD protein interactions reveals functional selectivity by distinct WNT-FZD pairs. J Biol Chem. 2015;290:6789–6798.  https://doi.org/10.1074/jbc.M114.612648.CrossRefGoogle Scholar
  23. 23.
    Behrens J, Jerchow BA, Wurtele M, et al. Functional interaction of an Axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science. 1998;280:596–599.CrossRefGoogle Scholar
  24. 24.
    Kim YD, Park CH, Kim HS, et al. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:110–118.  https://doi.org/10.1111/j.1440-1746.2007.05250.x.CrossRefGoogle Scholar
  25. 25.
    Zucman-Rossi J, Benhamouche S, Godard C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene. 2007;26:774–780.  https://doi.org/10.1038/sj.onc.1209824.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Xiaoling Luo
    • 1
  • Yuting Liu
    • 2
  • Shijie Ma
    • 1
  • Lei Liu
    • 2
  • Rui Xie
    • 1
  • Shaochuang Wang
    • 2
    Email author
  1. 1.Department of Gastroenterology, Huai’an First People’s HospitalNanjing Medical UniversityHuai’anPeople’s Republic of China
  2. 2.Department of Hepatobiliary and Pancreatic Surgery, Huai’an First People’s HospitalNanjing Medical UniversityHuai’anPeople’s Republic of China

Personalised recommendations